BridgeBio Pharma, Inc.BBIO

時価総額

$143.9億

PER

遺伝性疾患治療薬の研究開発の新興企業。治療候補のAttrubyやBeyonttraを展開。2024年1月の資金提供契約でFDA承認時に5億ドル受領見込み、2024年3月の公募で約2.77億ドルを調達。米国・欧州中心に展開。

	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Cash and cash equivalents	364	356	394	377	376	681
Marketable securities	182	251	394	52	-	-
Investments in equity securities	-	-	49	44	59	-
Accounts receivable	-	-	-	-	-	5
Receivables, Long-Term Contracts or Programs	-	-	20	17	2	-
Restricted cash	-	-	-	38	17	0
Prepaid expenses and other current assets	23	36	32	22	24	35
Total current assets	569	643	889	549	478	721
Investment in nonconsolidated entities	-	-	-	-	-	144
Property and equipment, net	6	20	30	15	12	7
Operating lease right-of-use assets	-	17	16	11	8	6
Intangible assets, net	-	-	45	29	26	24
Other assets	26	24	33	20	23	18
Total assets	632	704	1,013	623	546	919
Accounts payable	9	9	12	12	11	10
Accrued compensation and benefits	13	30	37	31	57	58
Accrued research and development liabilities	21	27	44	40	30	34
Operating Lease, Liability, Current	-	4	5	4	4	5
Deferred Revenue, Current	-	-	-	8	6	15
Accrued professional and other accrued liabilities	-	-	-	-	36	33
Total current liabilities	60	96	135	121	144	154
2029 Notes	-	-	733	735	737	739
2027 Notes	-	-	540	542	543	545
Notes, net	-	383	-	-	-	-
2029 Notes	-	-	733	-	-	-
2027 Notes	-	383	540	-	-	-
Term loan, net	92	92	431	431	446	437
Deferred royalty obligation, net	-	-	-	-	-	479
Operating Lease, Liability, Noncurrent	-	15	17	12	9	5
Deferred Revenue, Noncurrent	-	-	-	-	-	17
Other long-term liabilities	4	10	22	27	9	0
Total liabilities	156	596	1,878	1,868	1,889	2,377
Redeemable convertible noncontrolling interests	-	-	-	-2	0	0
Common Stock, Value, Issued	0	0	0	0	0	0
Treasury stock, at cost; 6,191,761 shares as of December 31, 2024 and December 31, 2023	-	75	275	275	275	275
Additional paid-in capital	848	1,021	842	939	1,481	1,903
Accumulated other comprehensive income	0	0	-0	-0	0	0
Accumulated deficit	-440	-889	-1,437	-1,918	-2,561	-3,096
Total BridgeBio stockholders' deficit	474	106	-867	-1,243	-1,343	-1,458
Noncontrolling interests	65	48	3	11	11	10
Total stockholders' deficit	474	106	-867	-1,243	-1,343	-1,458
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit	632	704	1,013	623	546	919